Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

A Comprehensive Overview of the Bipolar Spectrum

Listen as 2 experts in psychiatry provide an overview of the bipolar spectrum, including identifying bipolar depression with mixed presentations and various treatment strategies.
Charles DeBattista, DMH, MD
Greg W. Mattingly, MD
Released: July 7, 2022

In this episode, Drs Greg W. Mattingly and Charles DeBattista have a conversation about the history and features of the bipolar spectrum. Because patients can present in mixed vignettes, diagnosis of bipolar depression can be challenging. The experts offer insight on when to hold a suspicion for bipolar depression, as well as common presentations they have seen over their years in clinical practice. The conversation then progresses to potential “triggers” of bipolar depression and culminates with a discussion of the current treatment paradigm for patients with bipolar depression: first- or second-generation antipsychotics.

Information on this Educational Activity

Faculty

Greg W. Mattingly, MD

Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
Midwest Research Group
St. Louis, Missouri

Greg W. Mattingly, MD: speaker: AbbVie, Alkermes, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris Pharma; consultant: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neos, Neurocrine, Noven, Otsuka, Redax, Rhodes, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, Tris Pharma; researcher: AbbVie, Acadia, Akili, Alkermes, Axsome, Boehringer, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.
Charles DeBattista, DMH, MD

Chief, Depression Research Clinic
Director, Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Charles DeBattista, DMH, MD: researcher: Biolite, Compass, Janssen, Myriad, Neurocentria, Relmada, Sage; consultant: AbbVie, Corcept.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Intra-Cellular Therapies, Inc.

Related Content

Board-certified psychiatric pharmacist provides information on the pharmacokinetics and administration of long-acting injectable antipsychotics, from Clinical Care Options (CCO)

Austin Campbell, PharmD, BCCP Released: January 24, 2023

In this on-demand webcast, an expert faculty explores updates on identifying and managing tardive dyskinesia.

Leslie Citrome, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME Credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: January 23, 2023 Expired: January 22, 2024

In this on-demand webcast, an expert faculty describes the current and emerging treatment options for major depression

Greg W. Mattingly, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME Credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: January 20, 2023 Expired: January 19, 2024

Expert presentation on current and emerging treatments for bipolar depression with a focus on treatment with monoaminergic antidepressants, mood stabilizers, and specific second-generation antipsychotics, from Clinical Care Options (CCO)

Joseph F. Goldberg, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME Credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: January 20, 2023 Expired: January 19, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings